Literature DB >> 25416528

Poorly differentiated adenocarcinoma of the colon: subsite location and clinicopathologic features.

Yasuo Imai1.   

Abstract

PURPOSE: Colorectal cancers of the proximal colon are characterized by good prognosis, microsatellite instability (MSI), and poor differentiation. MSI is associated with a favorable prognosis, but poorly differentiated adenocarcinomas (PDAs) have a poor prognosis. In this study, we aimed to investigate this inconsistency by analyzing the heterogeneity of PDAs.
METHODS: A total of 156 surgically resected PDAs were analyzed according to tumor subsite by morphological and immunohistochemical analyses.
RESULTS: Proximal PDAs (n = 86) were significantly associated with females, older age, cytokeratin (CK) 20 downregulation, aberrant MUC5AC expression, and MSI compared with distal PDAs (n = 70). Proximal PDAs tended to show a better overall survival rate than distal PDAs. PDAs with microsatellite stability (MSS) were suggested to progress from well- and moderately differentiated adenocarcinomas (WMDAs), but MSI PDAs typically not. MSI PDAs demonstrated a prognosis marginally better than MSS PDAs, but significantly worse than WMDAs (n = 170). Proximal MSS PDAs had a similar unfavorable prognosis but were significantly associated with females and aberrant MUC5AC expression compared with distal MSS PDAs. MSI may be predictive of prognosis only in proximal PDAs, because nearly all distal PDAs were MSS. In contrast, CK20 downregulation was significantly associated with better prognosis in both subsites.
CONCLUSIONS: Proximal PDAs had a better prognosis than distal PDAs due to a higher incidence of MSI PDAs, whose prognosis was significantly worse than WMDAs. Female and MUC5AC expression were characteristic of proximal PDAs independent of MSI. Subsite-specific features of PDAs may serve for subclassification and predicting prognosis.

Entities:  

Mesh:

Year:  2014        PMID: 25416528     DOI: 10.1007/s00384-014-2070-0

Source DB:  PubMed          Journal:  Int J Colorectal Dis        ISSN: 0179-1958            Impact factor:   2.571


  42 in total

1.  Aberrant cytokeratin expression as a possible prognostic predictor in poorly differentiated colorectal carcinoma.

Authors:  Hidetsugu Yamagishi; Yasuo Imai; Takuya Okamura; Kazunori Fukuda; Yuko Ono; Shinichi Ban; Tohru Inoue; Yoshihiko Ueda
Journal:  J Gastroenterol Hepatol       Date:  2013-12       Impact factor: 4.029

2.  Tumor location is a prognostic factor in poorly differentiated adenocarcinoma, mucinous adenocarcinoma, and signet-ring cell carcinoma of the colon.

Authors:  Soichiro Ishihara; Toshiaki Watanabe; Takuya Akahane; Ryu Shimada; Atsushi Horiuchi; Hajime Shibuya; Tamuro Hayama; Hideki Yamada; Keijiro Nozawa; Keiji Matsuda; Koutarou Maeda; Kenichi Sugihara
Journal:  Int J Colorectal Dis       Date:  2011-11-04       Impact factor: 2.571

3.  Immunohistochemical staining patterns of MUC1, MUC2, MUC4, and MUC5AC mucins in hyperplastic polyps, serrated adenomas, and traditional adenomas of the colorectum.

Authors:  A E Biemer-Hüttmann; M D Walsh; M A McGuckin; Y Ajioka; H Watanabe; B A Leggett; J R Jass
Journal:  J Histochem Cytochem       Date:  1999-08       Impact factor: 2.479

4.  Transcriptional activation of the MUC2 gene by p53.

Authors:  Keizou Ookawa; Toshihiro Kudo; Shu Aizawa; Hiroshi Saito; Shigeki Tsuchida
Journal:  J Biol Chem       Date:  2002-10-08       Impact factor: 5.157

5.  Loss of MUC2 expression correlates with progression along the adenoma-carcinoma sequence pathway as well as de novo carcinogenesis in the colon.

Authors:  T Mizoshita; T Tsukamoto; K I Inada; N Hirano; M Tajika; T Nakamura; H Ban; M Tatematsu
Journal:  Histol Histopathol       Date:  2007-03       Impact factor: 2.303

6.  Clinical and pathological characteristics of sporadic colorectal carcinomas with DNA replication errors in microsatellite sequences.

Authors:  H Kim; J Jen; B Vogelstein; S R Hamilton
Journal:  Am J Pathol       Date:  1994-07       Impact factor: 4.307

7.  Early colorectal carcinomas: CD10 expression, mucin phenotype and submucosal invasion.

Authors:  Kimikazu Hirano; Satoshi Nimura; Mikio Mizoguchi; Yoshihiro Hamada; Yuichi Yamashita; Hiroshi Iwasaki
Journal:  Pathol Int       Date:  2012-09       Impact factor: 2.534

Review 8.  Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis.

Authors:  M S Greenblatt; W P Bennett; M Hollstein; C C Harris
Journal:  Cancer Res       Date:  1994-09-15       Impact factor: 12.701

Review 9.  Are there two sides to colorectal cancer?

Authors:  Barry Iacopetta
Journal:  Int J Cancer       Date:  2002-10-10       Impact factor: 7.396

10.  Antigens of gastric and intestinal mucous cells in human colonic tumours.

Authors:  J Bara; F Loisillier; P Burtin
Journal:  Br J Cancer       Date:  1980-02       Impact factor: 7.640

View more
  3 in total

1.  Mucins and associated glycan signatures in colon adenoma-carcinoma sequence: Prospective pathological implication(s) for early diagnosis of colon cancer.

Authors:  Shiv Ram Krishn; Sukhwinder Kaur; Lynette M Smith; Sonny L Johansson; Maneesh Jain; Asish Patel; Shailendra K Gautam; Michael A Hollingsworth; Ulla Mandel; Henrik Clausen; Wing-Cheong Lo; Wai-Tong Louis Fan; Upender Manne; Surinder K Batra
Journal:  Cancer Lett       Date:  2016-02-16       Impact factor: 8.679

2.  α-taxilin overexpression correlates with proliferation activity but not with prognosis of colorectal cancer.

Authors:  Akira Kanamori; Yasuo Imai; Keisuke Ihara; Hitoshi Nagata; Masakazu Nakano; Keiichi Tominaga; Hiroaki Shimizu; Tomihiko Makiyama; Hajime Kuroda; Hiromichi Shirataki; Hideyuki Hiraishi
Journal:  Oncol Lett       Date:  2017-06-02       Impact factor: 2.967

3.  Impact of histological subtype on prognosis in stage IV colorectal cancer: A population-based cohort study.

Authors:  Teppei Miyakawa; Hidetaka Kawamura; Michitaka Honda; Yoshinao Takano; Shunji Kinuta; Takahiro Kamiga; Shigeru Yamazaki; Atsushi Muto; Satoru Shiraso; Naoyuki Yamashita; Toshiyasu Iwao; Koji Kono; Shinichi Konno
Journal:  PLoS One       Date:  2022-03-03       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.